The Center for Data-Driven Drug Development and Treatment Assessment (DATA) advances U.S. competitiveness by working with industry to solve challenges in drug discovery and repurposing and in treatment assessment, optimization, and quantitative pharmacovigilance using novel computational and data science techniques such as metrology, machine learning (ML), and artificial intelligence (AI), and by training the next generation of talent in this field. With new methodologies and infrastructure for industry-wide collaboration, DATA seeks to significantly accelerate drug development to help target the right drug to the right person at a safe and effective dose while reducing R&D costs.
DATA’s mission is to address two principal areas of unmet or underserved computational research needs within the (bio)pharmaceutical and health care sectors:
The advent of generative AI has created an urgent need for stakeholders in all stages of the drug life cycle to come together, share experiences with this revolutionary technology, and jointly address its implications for health care. Thanks to its cross-industrial and cross-disciplinary nature designed to bring together data scientists, mathematicians, biomedical researchers, pharmaceutical companies, healthcare providers and payers, as well as government agencies, DATA is ideally positioned to catalyze these conversations, identify best practices, and develop solutions to the challenges generative AI brings to the health care sector.
The Center also addresses the growing demand for data science professionals with an expertise in drug design and treatment assessment by a robust education and training program focused on exposing the next generation of data science leaders to real-world needs and by connecting DATA industry partners with emerging talent in this field.
DATA's solutions are applicable at all stages of the drug discovery and treatment optimization pipeline, including during the initial screening for potential candidates, in the mechanistic & machine learning stage, during the testing of in-vitro/in-vivo disease models, in the assessment of clinical trials, through post-market pharmacovigilance and treatment monitoring. The Center will also have a broader impact on the society. For example, privacy-preserving and encryption techniques, while developed in the health care context, have a universal application and are readily transferable to other industries that handle sensitive identifiable information.
DATA's research program focuses on the following areas to advance the design, testing, validation and assessment of drugs and treatments: